CIK 0001812364 · Large accelerated filer
Relay Therapeutics, Inc.
Sign in to watch- Ticker
- RLAY
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-370-8837
- Business address
- 60 HAMPSHIRE STREET, CAMBRIDGE, MA, 02139
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $120,515,207
- in 12 filings, $4.0M under 10b5-1 plans
Net −$120,515,207. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 98 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-28 | Rahmer Peter See remarks | Sale | −753 | $18.62 | $14K | 222,904 |
| 2026-10-28 | Bergstrom Donald A President, R&D | Sale | −2,252 | $18.62 | $42K | 396,878 |
| 2026-10-28 | Catinazzo Thomas Chief Financial Officer | Sale | −1,469 | $18.62 | $27K | 103,665 |
| 2026-10-07 | Patel Sanjiv President and CEO | Sale 10b5-1 | −48,199 | $18.10 | $872K | 471,301 |
| 2026-10-06 | Catinazzo Thomas Chief Financial Officer | Sale 10b5-1 | −17,511 | $18.58 | $325K | 105,340 |
| 2026-10-06 | Catinazzo Thomas Chief Financial Officer | Sale 10b5-1 | −206 | $19.26 | $4K | 105,134 |
| 2026-09-08 | Bergstrom Donald A President, R&D | Sale 10b5-1 | −8,530 | $18.97 | $162K | 399,130 |
| 2026-09-08 | Catinazzo Thomas Chief Financial Officer | Sale 10b5-1 | −17,717 | $18.94 | $336K | 122,851 |
| 2026-09-08 | Patel Sanjiv President and CEO | Sale 10b5-1 | −48,199 | $18.94 | $913K | 519,500 |
| 2026-08-26 | Rahmer Peter See remarks | Sale 10b5-1 | −4,508 | $20.03 | $90K | 223,657 |
| 2026-08-25 | SVF Pauling (Cayman) Ltd 10% owner | Sale | −6,000,000 | $19.40 | $116.4M | 21,904,963 |
| 2026-08-17 | Patel Sanjiv President and CEO | Sale 10b5-1 | −48,199 | $20.33 | $980K | 567,699 |
| 2026-08-14 | Catinazzo Thomas Chief Financial Officer | Sale 10b5-1 | −17,717 | $19.74 | $350K | 140,568 |
| 2026-07-28 | Catinazzo Thomas Chief Financial Officer | Sale | −1,459 | $18.61 | $27K | 158,285 |
| 2026-07-28 | Rahmer Peter See remarks | Sale | −748 | $18.61 | $14K | 228,165 |
| 2026-07-28 | Bergstrom Donald A President, R&D | Sale | −2,237 | $18.61 | $42K | 407,660 |
| 2026-07-07 | Patel Sanjiv President and CEO | Sale 10b5-1 | −48,199 | $19.58 | $944K | 615,898 |
| 2026-07-06 | Bergstrom Donald A President, R&D | Sale 10b5-1 | −8,660 | $18.71 | $162K | 409,897 |
| 2026-07-06 | Catinazzo Thomas Chief Financial Officer | Sale 10b5-1 | −17,717 | $18.69 | $331K | 159,744 |
| 2026-06-30 | Patel Sanjiv President and CEO | Grant or award 10b5-1 | +3,056 | $6.95 | $21K | 664,097 |
Page 1 of 17 · 329 trades